Berberine (BBR) is a compound originally identified in a Chinese herbal medicine Huanglian (Coptis chinensis French). It improves glucose metabolism in type 2 diabetic patients. The mechanisms involve in activation of adenosine monophosphate activated protein kinase (AMPK) and improvement of insulin sensitivity. However, it is not clear if BBR reduces blood glucose through other mechanism. In this study, we addressed this issue by examining liver response to BBR in diabetic rats, in which hyperglycemia was induced in Sprague-Dawley rats by high fat diet. We observed that BBR decreased fasting glucose significantly. Gluconeogenic genes, Phosphoenolpyruvate carboxykinase (PEPCK) and Glucose-6-phosphatase (G6Pase), were decreased in liver by BBR. Hepatic steatosis was also reduced by BBR and expression of fatty acid synthase (FAS) was inhibited in liver. Activities of transcription factors including Forkhead transcription factor O1 (FoxO1), sterol regulatory element-binding protein 1c (SREBP1) and carbohydrate responsive element-binding protein (ChREBP) were decreased. Insulin signaling pathway was not altered in the liver. In cultured hepatocytes, BBR inhibited oxygen consumption and reduced intracellular adenosine triphosphate (ATP) level. The data suggest that BBR improves fasting blood glucose by direct inhibition of gluconeogenesis in liver. This activity is not dependent on insulin action. The gluconeogenic inhibition is likely a result of mitochondria inhibition by BBR. The observation supports that BBR improves glucose metabolism through an insulin-independent pathway.
Citation: Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y, et al. (2011) Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis. PLoS ONE 6(2): e16556. https://doi.org/10.1371/journal.pone.0016556
Editor: Aimin Xu, University of Hong Kong, China
Received: September 1, 2010; Accepted: January 1, 2011; Published: February 3, 2011
Copyright: © 2011 Xia et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by 973 Program of China 2006CB503902, Program for Changjiang Scholars and Innovative Research Team in University (985 project PCSIRT 0947), National Science Fund for Distinguished Young Scholars 81025005 (to Jianping Weng). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Berberine (BBR, C20H18NO4) is an isoquinoline alkaloid originally isolated from the Chinese herb Coptis chinensis (Huanglian) . BBR is widely used to reduce blood glucose in type 2 diabetes in China . The mechanism is related to activation of AMPK (Adenosine monophosphate-activated protein kinase), ACC (acetyl-CoA carboxylase) and improvement of fatty acid oxidation . BBR may improve insulin sensitivity through AMPK pathway or induction of insulin receptor expression , , . We reported that AMPK activation by BBR is dependent on mitochondrial inhibition , which leads to an increase in the AMP/ATP(adenosine mono-phosphate/adenosine triphosphate) ratio in cells after BBR treatment. The AMP elevation is a result of the complex I inhibition in the mitochondrial respiratory chain . The complex I inhibition blocks AMP conversion into ATP in the mitochondria. Therefore, BBR may reduce fasting blood glucose through an insulin-independent signaling pathway, such as AMPK activation and insulin receptor expression. This pathway is important in the skeletal muscle and adipose tissue in the insulin-induced glucose deposition. Hepatic gluconeogenesis contributes to elevation of fasting glucose, and requires mitochondrial production of ATP. We propose that the mitochondrial inhibition by BBR may contribute to the fasting glucose reduction through ATP depletion. In this study, we addressed this issue by studying hepatic gluconeogenesis in diabetic rats.
Hyperglycemia in type 2 diabetes is characterized by enhanced glucose production in the liver and kidney. Fasting blood glucose is determined by de novo glucose production (in liver and kidney) and glucose deposition in peripheral tissues. In the presence of insulin resistance, enhanced glucose output by liver contributes to hyperglycemia together with reduced glucose deposition in skeletal muscle, heart and adipose tissue. Inhibition of hepatic glucose production contributes to glycemic control in the diabetic patients by insulin sensitizers. Insulin inhibits expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), two rate-limiting genes in gluconeogenesis. These genes are induced by glucagon and reduced by insulin. Activation and inhibition of transcription factors including forkhead transcription factor O1 (FoxO1), hepatic nuclear factor 4 (HNF4), and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) are the underlying mechanism of the hormone actions , , . The activities of these transcription factors are highly dependent on ATP supply. In the transcriptional process, transcriptional initiation, RNA elongation and RNA splicing all requires ATP supply, which provides energy to enzymes at each step. When ATP is reduced in cells, such as under hypoxia, gene transcription is suppressed in response to energy depletion . Additionally, mRNA translation will be decreased leading to suppression of protein synthesis. The reduction in gene transcription and protein synthesis may lead to inhibition of hepatic gluconeogenesis. Given that BBR inhibits mitochondrial function, this possibility may represent a new mechanism for BBR in the control of blood glucose.
In the present study, we examined the molecular mechanism of hepatic gluconeogenesis in response to BBR in rats. We observed: (1) BBR decreased fasting blood glucose and expression of key gluconeogenic genes, such as PEPCK and G6Pase; (2) BBR suppressed the transcription factors, FoxO1 and sterol regulatory element-binding protein 1c (SREBP1); (3) BBR inhibited mitochondrial function in hepatocytes.
Materials and Methods
Type 2 diabetes rat model
The type 2 diabetic rat model was developed using male Sprague-Dawley rats (7–8 weeks, 200∼250 g) according to a protocol published elsewhere . The rats were fed on high fat diet (63.47% calorie in fat) for 8 weeks, and then followed by a single low-dosage intraperitoneal injection of streptozotocin (STZ, 30 mg/kg, Sigma, St Louis, MO) after 12-hour fast. The non-diabetic control rats were fed on chow diet. Diabetic rats were divided into two subgroups: vehicle treated and BBR treated (n = 9). Non-diabetic rats were subgrouped in the same way. Plasma glucose increased in diabetic rats to 16.7 mmol/L within 3 days after STZ treatment and remained at this level throughout the experiment. These rats were used in the type 2 diabetic model. All procedures were performed in accordance with the principles of laboratory animal care (National Institutes of Health publication no. 85-23, revised 1985) and the animal protocol was approved by the Sun Yat-Sen University, Institutional Animal Care and Use Committee (IACUC, Approval ID:2008010102).
The BBR intervention was initiated on the third day after STZ injection and conducted for five weeks. BBR solution was prepared in PBS and delivered by oral gavage at dosage of 380 mg·kg−1·d−1. The control group was given vehicle PBS.
Blood and liver collection
After five weeks' BBR treatment, liver and blood were collected from each rat under anesthetized. Blood was collected from abdominal aorta using syringe puncture. Liver was removed and divided into three pieces, which were subjected to 4% formaldehyde fixation, Oil Red O staining and protein/RNA extraction. Tissue for protein/RNA preparation was stored in −80°C freezer after snap-frozen in liquid nitrogen. The sample collection was conducted in fasting (12-hour) and non-fasting conditions, respectively.
Fasting blood glucose was determined in the tail vein blood using portable glucometer (Roche, Basel, Switzerland). Blood insulin was measured in serum derived from the abdominal aorta blood with an insulin radioimmunoassay kit, which was purchased from Linco Research (Missouri, USA). Serum triglyceride and total cholesterol, alanine aminotransferase (ALT) and aspartate transaminase (AST) were determined using automatic biochemistry analyzer. Energy balance (diet intake, calorie intake, urine volume, and body weight) was monitored in individual rat for 3 consecutive days using a “metabolic cage”. The data were collected every day.
Glucose tolerance and insulin tolerance tests
Oral glucose tolerance test (GTT) was performed 48 hours after the five-week BBR intervention. Glucose (2.0 g·kg−1 body weight) was administered through oral gavage after 12-hour fast. Blood glucose was determined at 0, 30, 60, 90 and 120 minutes after glucose challenge. Insulin tolerance test was carried out by intraperitoneal injection with insulin (0.75 U.kg−1 body wt). Blood glucose was checked at 0, 15, 30, 45, 60, and 90 minutes after insulin injection. Food intake, urine volume, diet intake were tested in each rat individually.
Insulin releasing test
Insulin releasing test (IRT) was performed during the glucose tolerance test. Serum sample was collected at 0, 15, 30, 60, 90 and 120 minutes after glucose gavage. Serum insulin was determined by radioimmunoassay kit (Linco Research, Missouri, USA).
Preparation for total, nuclear and cytoplasmic protein extracts
To determine insulin signaling activity, we collected the liver tissue at 30 minutes after intraperitoneal insulin injection (0.75 U.kg−1 body wt) and stored the samples at −80°C. The frozen liver sample was minced in ice cold phosphate buffered saline and homogenized in cell lysis buffer (Cell Signaling Technology Inc., Danvers, MA). The whole cell protein was collected after centrifugation at 4°C. The protein concentration was measured using the BCA protein assay kit (Sangon Biotech, Shanghai, China). The nuclear and cytoplasm protein were extracted from liver tissue using a Nuclear Extraction Kit (Chemicon, Inc, USA).
Protein (30 µg) was resolved in 10% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and transferred to a PVDF membrane. The antibodies to Akt (Protein kinase B, PKB), PEPCK, G6Pase, fatty acid synthase (FAS), FoxO1, SREBP1, SREBP2, carbohydrate responsive element-binding protein (ChREBP), TFIID (the TATA box binding protein, TBP) were purchased from the Santa Cruz Biotechnology (CA, USA). Antibodies to glyceraldehyde-3-phosphate dehydrogenase (GADPH) and β-actin were from the Cell Signaling Technology, USA. The peroxide-conjugated anti-rabbit antibody (Boster, Wuhan, China) was used to detect the protein signal with enhanced chemiluminescence system (Pierce, USA). The band intensity was quantified by densitometry (Calibrate densitometer, Bio-Rad, Inc).
RNA isolation and quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR)
Total RNA was extracted from the frozen liver tissues using the TRIzol RNA isolation reagent (Invitrogen, Carlsbad, CA). Reverse transcription of 1 µg RNA was carried out according to the instructions of Prime Script™ 1st Strand cDNA Synthesis Kit (TaKaRa, Japan). The qRT-PCR reaction was conducted in 20 µl (SYBR® Premix Ex TaqTM, TaKaRa Japan). The result was normalized against β-actin mRNA signal. Primer sequences were as follows: Rat PEPCK forward primer (5′-CTCACCTCTGGCCAAGATTGGTA-3′) and reverse primer (5′-GTTGCAGGCCCAGTTGTTGA-3′); Rat G6Pase forward primer (5′-AACGTCTGTCTGTCCCGGATCTAC-3′) and reverse primer (5′-ACCTCTGGAGGCTGGCATTG-3′); Rat FAS forward primer (5′-CACAGCATT CAGTCCTATCCACAGA-3′) and reverse primer (5′-CACAGCCAACCAGATGCTTCA-3′); Rat FoxO1 forward primer (5′-TGCCAAACTCACTACACCACTT-3′) and reverse primer (5′-ACGATCAGGTTCCGTCATTC-3′); Rat β-actin forward primer (5′-GGAGATTACTGCCCTGGCTCCTA-3′) and reverse primer (5′-GACTCA TCGTACTCCTGCTTGCTG-3′).
The liver sample fixed in 4% Para formaldehyde was paraffin-embedded, sectioned at 8 µm in thickness and stained with hematoxylin & eosin dye (HE) and immunohistochemistry (DAB staining). The frozen samples were sectioned and stained with Oil Red O and Sudan III. The immunohistostaining was performed according to instruction of the SABC assay (Boster, Wuhan, China). Paraffin-embedded sections were deparaffinized using xylene and re-hydrated in a series of alcohols, and incubated in antigen retrieval (0.01 M citrate buffered saline, pH 6.0) for 5 min at 95°C and then for 20 min at room temperature. The sections were then treated with 3% hydrogen peroxide for 5 min. The slide was treated with 10% normal goat serum to prevent nonspecific antibody binding. The sample was treated with the primary antibody overnight at 4°C in PBS. Imaging was obtained using a Nikon microscope and analyzed by software (HMIAS-2000, Championimage Inc, China).
Oxygen consumption and AMP/ATP ratio
Oxygen consumption and AMP/ATP ratio were examined in H4IIE hepatocytes using protocols reported elsewhere . The cells were cultured in a plate embedded with an oxygen-sensitive dye. After 6 hrs, BBR was added to the medium to treat cells for 12 hrs. The oxygen consumption was determined by the fluorescence intensity in the oxygen-sensitive dye, and expressed as relative fluorescence units (NRFU). The reading was normalized with the background in a blank well. The cells were treated with 20 µM BBR for 16 hrs in serum-free medium containing 0.25% BSA. The cells were lyzed in 0.6 N HClO4 and neutralized with 1 N KHCO3. Then AMP and ATP contents were measured using high-performance liquid chromatography (HPLC).
The results were expressed as the means ± SE. The significant difference in two groups was statistically analyzed using the Student's t test. The significant difference in more than two groups was statistically analyzed using ANOVA. The least-square deconvolution (LSD) was performed to detect differences between two groups. Statistical significance was set at P<0.05 (two tails).
Characteristics of the experimental animals treated by BBR
To investigate BBR action in liver, we used diabetic rats, which were generated after 8 weeks high fat diet feeding and a single streptozotocin treatment. The rats were treated with BBR through oral gavage for 5 weeks, and then subjected to variety of tests. BBR reduced body weight, fasting blood glucose, total cholesterol, and triglycerides in the diabetic rats (Table 1). Calorie intake, serum insulin, urine volume, water intake, serum ALT, and AST were not altered by BBR. These data suggest that the reduction in blood glucose and lipids may be a result of enhanced energy expenditure in the rats. These were observed with reduced body weight in the absence of food intake reduction. The body weight was also decreased in the non-diabetic rats (lean rats) by BBR (Table 1), suggesting that BBR reduces body weight in both obese and lean rats.
Systemic insulin sensitivity was evaluated by fasting glucose, GTT and ITT. In the GTT test, the BBR group exhibited lower blood glucose than the un-treated control at the basal level (Fig. 1A). After oral glucose challenge, the untreated group had little increase in blood glucose. The blood glucose only increased modestly by the glucose challenge. However, the BBR group exhibited a dramatic increase in blood glucose at 30 and 60 minutes. The glucose reached to the same level as the untreated group at 90 and 120 minutes. In the test, blood insulin was monitored at each time point to determine the pancreatic beta cell function. The BBR group and untreated group had identical basal insulin. However, the BBR group exhibited a significantly higher insulin level than the untreated group between 15–60 minutes after the glucose challenge (Fig. 1B). In the ITT test, both the BBR group and untreated group exhibited similar change in percentage of blood glucose at 60–90 minutes, but the BBR group had less response than the untreated group during 15–45 minutes (Fig. 1C), suggesting a delayed response to insulin in the BBR group. Those data demonstrate that BBR reduces fasting blood glucose without altering blood insulin in the basal condition, suggesting an increase in systemic insulin sensitivity by HOMA-IR. Though GTT and ITT results do not support that systemic insulin sensitivity was improved by BBR, the results may not be definitive. Hyperinsulinemic-euglycemic clamping is required to determine insulin sensitivity.
(A) Effects of BBR treatment on OGTT in diabetic rats. Oral glucose tolerance test (OGTT) was conducted with glucose 2 g.kg−1 body wt after 5 week BBR treatment (380 mg.kg−1 day−1) (n = 6). (B) Insulin release during the OGTT (n = 6). (C) ITT test (n = 6). The test was conducted after 8 hour fasting with insulin (0.75 U.kg−1 body wt). Nor, normal rats without obesity; Diab+Veh: Diabetic rats treated with vehicle; Diab+BBR, diabetic rats treated with BBR. # P<0.05, compared with Diab+Veh. (D) Insulin signaling. Phosphorylation of Akt (Ser473). Rats were challenged with insulin (0.75 U.kg−1, intraperitoneal injection) and liver was collected in 30 minutes. The Akt assay was performed in a Western blot. Loading control is GAPDH. (E) Expression and phosphorylation of AMPK (Thr172). # P<0.05, compared with Diab+Veh group. * P<0.05, compared with normal group (Nor).
To test insulin action in liver, we examined the insulin signaling activity by checking Akt phosphorylation status in response to insulin. Liver was collected from rats in 30 minutes after insulin challenge. Akt phosphorylation status was determined using a phospho-specific antibody in a Western blot. The phosphorylation was not significantly improved in the BBR group (Fig. 1D), suggesting that BBR treatment does not improve insulin signaling in liver. We also examined AMPK in the liver. AMPK protein and its phosphorylation were both reduced in the diabetic rats (Fig. 1E). In the BBR group, the reduction was not observed, suggesting that BBR may protect the AMPK activity. AMPK improves glucose uptake by stimulating GLUT4 translocation in adipocytes and muscle cells. In hepatocytes, this mechanism is not working since hepatocytes do not express GLUT4. The data suggest that BBR does not alter insulin signaling pathway in liver.
Berberine inhibits the expression of gluconeogenic genes in liver
To investigate hepatic gluconeogenesis, we examined expression of PEPCK and G6Pase in liver. PEPCK and G6Pase are two rate-limiting enzymes in the gluconeogenic process in hepatocytes. The protein levels of PEPCK and G6Pase are primarily controlled by gene transcription. In the liver of BBR group, both enzymes were reduced significantly in proteins (Fig. 2A). The changes were observed in both fasting and fed conditions. mRNA of PEPCK and G6Pase was also decreased in the BBR group, suggesting that protein reduction is a result of mRNA reduction (Fig. 2B and 2C). The inhibition was observed in the fasting condition, when insulin level is low in the blood (Table 1). Although insulin inhibits the two enzyme expression, the data do not support a role of insulin. The data suggest that BBR suppresses PEPCK and G6Pase expression independently of insulin.
(A) Protein levels of PEPCK and G6Pase. Total protein was made from liver tissue and used in a Western blot. (B) mRNA in fasting condition. Total RNA was extracted in from liver tissue and used in qRT-PCR. The signal was normalized with actin mRNA. (C) mRNA in fed condition. The mRNA data are presented as mean ± SEM (n = 6). # P<0.05, compared with Diab+Veh group. * P<0.05, compared with normal group (Nor).
Berberine inhibits FoxO1 in liver
FoxO1 is an important transcription factor in the control of gluconeogenesis in liver . FoxO1 induces PEPCK and G6Pase gene transcription to initiate gluconeogenesis. This activity is dominant in fasting condition in the absence of a high level of insulin, which inactivates the transcriptional activity of FoxO1 through Akt-mediated nucleus exclusion and protein degradation of FoxO1. To understand the mechanism of PEPCK and G6Pase inhibition by BBR, we examined FoxO1 protein and mRNA in the liver. FoxO1 protein was higher in the liver of diabetic rats relative to the non-diabetic control (Fig. 3A). The elevation may be a result of reduced insulin activity from the low levels of insulin and insulin sensitivity in the diabetic rats. The FoxO1 protein was reduced by BBR. The reduction was observed in both cytoplasm and nucleus. However, the nuclear reduction was much stronger (Fig. 3A). The protein reduction was also observed in the liver tissue by immunohistostaining (DAB dye) (Fig. 3B). FoxO1 mRNA was reduced by BBR, and the inhibition degree was identical in both fasting and fed conditions (Fig. 3C). Given that insulin is low in the fasting condition, the data suggest that BBR inhibits FoxO1 expression independently of insulin.
(A) FoxO1 protein in liver. Nuclear and cytoplasmic proteins were extracted from liver and analyzed in a Western blot. TBP (TATA-binding protein) and GAPDH proteins are loading controls in the nuclear and cytoplasmic proteins. (B) Immunohistostaining of FoxO1 protein in liver. DAB dye (brown) was used to indicate the FoxO1 protein signal; (C) mRNA expression of FoxO1. mRNA was quantified in real time RT-PCR (n = 6). # P<0.05, compared with Diab+Veh group; * P<0.05, compared with normal group (Nor).
Berberine inhibits lipid accumulation in liver
Lipid accumulation in liver impairs hepatocyte function leading to hyperglycemia through hepatic glucose production. We examined BBR impact on fat content in liver in the BBR-treated rats. Liver tissue was analyzed under microscope after HE staining and Oil Red O staining. Lipid accumulation was elevated in the diabetic rats as indicated by the unstained area in hepatocytes under HE staining (Fig.4A), and red color in hepatocytes under the Oil Red O or Sudan III staining (Fig. 4, B and C). The hepatocyte density and proliferation status were determined with DNA staining in blue color by hematoxylin (Fig. 4, A and C). Hepatocyte proliferation was enhanced in the diabetic condition as indicated by the loosen chromatin DNA in the nucleus of hepatocytes in the diabetic group (Fig. 4, A and C). The unpacking process is required for DNA duplication and chromosome doubling. In the BBR group, the change in DNA was inhibited, and DNA was packed tightly in the nucleus, suggesting a reduction in cell proliferation. The cell density was not altered by BBR. The data suggest that BBR inhibits lipid accumulation in hepatocytes. This is not a result of liver toxicity since BBR did not reduce cell density in liver. BBR may inhibit the metabolic activity in hepatocytes as cell proliferation activity is reduced by BBR.
Berberine ameliorates fatty acid synthesis in liver by inhibiting expression of SREBP1 and FAS
SREBP1 and ChREBP are transcription factors for lipogenic gene expression, such as FAS , . Inhibition of SREBP1 by gene knockout was reported to decrease lipid accumulation in liver . SREBP2 is an isoform of SREBP1 and has an activity in induction of cholesterol synthetic genes. It was reported that BBR reduces SREBP2 expression in hepatocytes . To understand the molecular basis of lipid reduction in liver, we measured expression of SREBP1, SREBP2, ChREBP and FAS. Three genes were reduced in liver by BBR (Fig. 5). The SREBP1 total protein was determined in the liver tissue lysate and was decreased by BBR (Fig. 5A). A reduction was also observed in ChREBP. SREBP2 was not changed in the same condition. FAS expression was increased in liver under the fed condition (Fig. 5, B and C). The increase was observed even in the non-diabetic rats. However, in the diabetic rats, the increase was enhanced much more, suggesting a more active fatty acid synthesis in response to feeding. In response to the BBR treatment, the FAS increase was attenuated (Fig. 5, B and C). The reduction was observed in the diabetic rats as well as in the non-diabetic mice. These data suggest that BBR inhibits FAS through suppression of SREBP1 and ChREBP expression. The inhibition represents a mechanism of BBR prevention of fatty liver.
(A) Lipogenic transcription factor proteins. Liver total protein was used in the Western blot. SREBP1, SREBP2 and ChREBP were detected in the fasted liver with specific antibodies. Beta-actin is a loading control. (B) FAS protein. The protein was detected in a Western blot in the fasted and fed liver, respectively. (C) FAS mRNA. mRNA was detected by qRT-PCR and normalized with beta-actin mRNA (n = 6). # P<0.05, compared with Diab+Veh group; * P<0.05, compared with normal group (Nor).
Inhibition of mitochondrial function in hepatocytes by BBR
Mitochondria are the major subcellular organs in oxygen consumption. In mitochondria, oxygen is used to oxidize glucose and fatty acids in the production of ATP. The side products are water and carbon dioxide in mitochondria. Although ATP is also made in glycolysis, the efficiency of ATP production is much lower in this mitochondria-independent pathway. Glycolysis becomes dominant when mitochondrial function is inhibited for ATP production. Mitochondrial inhibition leads to reduction in oxygen consumption and an increase in the AMP/ATP ratio. Therefore, oxygen consumption and AMP/ATP ratio are two major indicators of mitochondrial function. In an early study, we reported that BBR inhibited mitochondrial function in adipocytes and myotubes . The effect was not tested in hepatocytes. To test the role of mitochondrial inhibition in liver, we examined mitochondrial function in hepatocytes after BBR treatment in cell culture. BBR decreased oxygen consumption and increased AMP/ATP ratio in H4IIE cells, a rat hepatoma cell line (Fig. 6, A and B). The data suggest that the BBR suppresses mitochondrial function in hepatocytes. This activity may account for the reduced gene expression for gluconeogenesis and fatty acid synthesis in liver.
(A) BBR decreased oxygen consumption in H4IIE hepatocytes. The cells were plated in DMEM culture medium supplemented with 10% FBS. Oxygen consumption was determined for 12 hrs after BBR (20 µM) treatment. (B) AMP/ATP ratio in H4IIE cells. The cells were treated with BBR in serum-free medium for 16 hours. AMP and ATP levels were determined using HPLC. The data are presented as mean ± SEM (n = 5). * P<0.05.
Our data suggest that BBR inhibits glucose production in liver. The inhibition is related to suppression of PEPCK and G6Pase expression. This is a new mechanism for BBR action in the regulation of glucose metabolism. In literature, BBR is reported to enhance insulin sensitivity in adipocytes and muscle cells. Activation of the AMPK pathway is a mechanism of enhanced glucose uptake in skeletal muscle , . However, the role of AMPK pathway is controversial for the metabolic activities of BBR. The AMPK activity was reported in muscle (L6) and hepatocytes (HepG2) , , but the activity was not observed in 3T3-L1 adipocytes . In HepG2 cells, AMPK was reported to mediate BBR activity in the inhibition of cholesterol and triglyceride synthesis . However, AMPK was not tested in BBR action in the regulation of hepatic gluconeogenesis. In the current study, we addressed this issue by examining AMPK and gluconeogenesis in liver. We observed that BBR improved AMPK activity and inhibited gluconeogenic gene expression at the same time. In the diabetic rats, BBR treatment restored AMPK activity to the level of non-diabetic rats. The change in AMPK activity is associated with a reduction in PEPCK and G6Pase expression. AMPK activation is proposed as a result of mitochondria inhibition by BBR , . Here, our data suggest that mitochondria inhibition is also a mechanism for suppression of hepatic gluconeogenesis and lipogenesis. The inhibition leads to suppression of gene expression and catalytic inactivation of related enzymes in liver through depletion of ATP. Recent literature supports that BBR increases glucagon-like peptide-1 (GLP-1) level in vivo and in vitro , . This activity of BBR may contribute to AMPK activation by BBR as well.
We demonstrated that insulin signaling was not significantly modified by BBR in liver. BBR was reported to enhance glucose uptake through GLUT4 translocation in skeletal muscle , . However, this mechanism is controversial as the GLUT4 activity was not confirmed in other studies , . Our data suggest that even this AMPK-GLUT4 interaction is a mechanism for BBR action in vivo, its contribution to glucose metabolism in whole body is limited. Our data do not support the mechanism in vivo as the insulin sensitivity was not significantly improved by BBR in the diabetic rats. This conclusion is supported by a recent study, in which BBR was shown to cause muscle atrophy through induction of protein degradation . This report argues against the BBR activity in insulin sensitization in muscle since insulin is known to prevent muscle atrophy , . In the current study, we examined the insulin signaling pathway in liver by determining Akt phosphorylation status. We did not observe a significant change in the insulin signaling pathway following the BBR treatment. The current study suggests that BBR may regulate glucose metabolism independently of insulin signaling pathway in liver.
Inhibition of mitochondria ATP production may contribute to the suppression of hepatic gluconeogenesis and hepatic steatosis. We observed that oxygen consumption was reduced and the AMP/ATP ratio was increased by BBR in hepatocytes. The data provide evidence for this new action of BBR in mitochondria suppression in hepatocytes. This observation is consistent with BBR activity in the purified mitochondria, in which BBR inhibited NAD-linked respiration in mitochondria , , . In hepatocytes, we observed that BBR enhanced lactate release , a sign of the mitochondria inhibition. Here, we demonstrated that oxygen consumption was reduced in hepatocytes by BBR, and this reduction was associated with an increase in AMP/ATP ratio. Though ATP production pathway is switched from mitochondrial oxidative phosphorylation to glycolysis in the presence of BBR, the glycolysis-generated ATP is not sufficient to maintain the intracellular ATP level in hepatocytes. The ATP depletion should account for inhibition of PEPCK and G6Pase expression through inactivation of transcription factors, whose activities are dependent on ATP.
The mitochondrial inhibition is a mechanism for inhibition of lipid accumulation in liver. We observed that BBR reduced hepatic steatosis in the diabetic rats. The mechanism is likely inhibition of lipogenesis in liver. BBR was shown to reduce plasma lipid and reduce plasma hepatic enzymes (ALT, AST, GGT) , . This BBR activity was confirmed in the current study. In term of mechanism, BBR is reported to inhibit cholesterol synthesis and induce LDLR expression , . In the current study, we observed that BBR inhibited fatty acid synthesis in liver. BBR inhibited FAS gene expression. Expression of lipogenic transcription factors (SREBP and ChREBP) was also reduced, which provides a mechanism for the FAS inhibition. Given that ATP is required for expression and function of the lipogenic transcription factors, the ATP depletion provides an answer to the lipogenic inhibition by BBR. The lipogenic inhibition may contribute to body weight loss in the BBR-treated rats observed in this study. BBR did not reduce food intake in our study. It has been reported that BBR does not affect expression of the appetite-regulating neuropeptides (POMC and NPY) in the hypothalamus in rodents . Therefore, the reduction in hepatic steatosis is not a consequence of alteration in calorie intake.
Pharmacokinetics of BBR is different among tissues . This character explains the long lasting AMPK activation that is observed in the current study. Recent studies suggest that: 1) BBR has a long half life in the liver. The BBR clearance rate is quite different among tissues, such as hippocampus VS plasma . According to a recent report, there is a 70-fold difference in the BBR clearance rate in liver VS plasma in rats . The studies suggest that BBR may have a longer half life in liver for the AMPK activation; 2) GLP-1 may mediate BBR's long-standing effect. BBR increases L cell activity in expression of GLP-1 in vivo , . The improved L cell activity may remain in the absence of BBR for the elevated GLP-1 expression. If this is the case, GLP-1 will mediate BBR activity in the AMPK activation in liver after BBR withdrawn. In the future, we will test this possibility by examining GLP-1 level in our models.
In summary, we conclude here that BBR reduces fasting blood glucose, attenuates gluconeogenesis and hepatic steatosis in type 2 diabetic rats (Fig. 7). Suppression of hepatic gluconeogenesis provides an excellent mechanism for the reduction in blood glucose. Inhibition of PEPCK and G6Pase expression is associated with decreased expression of transcription factors (FoxO1, SREBP1 and ChREBP) in the liver. BBR suppresses mitochondria function in hepatocytes to reduce ATP level. ATP depletion is a potential mechanism for BBR action in the inhibition of gluconeogenesis and lipogenesis in liver. The study suggests that inhibition of mitochondrial function in liver is responsible for the metabolic activities of BBR.
BBR inhibits mitochondria function and decrease intracellular ATP. This leads to a reduction in gluconeogenic and lipogenic transcription factors (FoxO1, SREBP1, and ChREBP). As a result, expression of gluconeogenic genes (PEPCK and G6Pase) and lipogenic gene (FAS) are decreased. These molecular changes represent a signaling pathway for improvement of fasting glucose and liver steatosis in the BBR-treated diabetic rats.
Conceived and designed the experiments: JW J. Ye. Performed the experiments: XX YZ KT YS DY J. Ye. Analyzed the data: XX J. Yan. Contributed reagents/materials/analysis tools: JW LH. Wrote the paper: XX J. Ye J. Yan.
- 1. Yin J, Zhang H, Ye J (2008) Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 8: 99–111.J. YinH. ZhangJ. Ye2008Traditional chinese medicine in treatment of metabolic syndrome.Endocr Metab Immune Disord Drug Targets899111
- 2. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, et al. (2006) Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States. Diabetes 55: 2256–2264.YS LeeWS KimKH KimMJ YoonHJ Cho2006Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States.Diabetes5522562264
- 3. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, et al. (2009) Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 58: 109–119.WJ KongH. ZhangDQ SongR. XueW. Zhao2009Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression.Metabolism58109119
- 4. Zhang H, Wei J, Xue R, Wu JD, Zhao W, et al. (2010) Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59: 285–292.H. ZhangJ. WeiR. XueJD WuW. Zhao2010Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.Metabolism59285292
- 5. Yin J, Gao Z, Liu D, Liu Z, Ye J (2008) Berberine Improves Glucose Metabolism through Induction of Glycolysis. Am J Physiol Endocrinol Metab 294: E148–E156.J. YinZ. GaoD. LiuZ. LiuJ. Ye2008Berberine Improves Glucose Metabolism through Induction of Glycolysis.Am J Physiol Endocrinol Metab294E148E156
- 6. Turner N, Li JY, Gosby A, To SW, Cheng Z, et al. (2008) Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57: 1414–1418.N. TurnerJY LiA. GosbySW ToZ. Cheng2008Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action.Diabetes5714141418
- 7. Roesler WJ, Vandenbark GR, Hanson RW (1989) Identification of multiple protein binding domains in the promoter-regulatory region of the phosphoenolpyruvate carboxykinase (GTP) gene. J Biol Chem 264: 9657–9664.WJ RoeslerGR VandenbarkRW Hanson1989Identification of multiple protein binding domains in the promoter-regulatory region of the phosphoenolpyruvate carboxykinase (GTP) gene.J Biol Chem26496579664
- 8. Chakravarty K, Cassuto H, Reshef L, Hanson RW (2005) Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Crit Rev Biochem Mol Biol 40: 129–154.K. ChakravartyH. CassutoL. ReshefRW Hanson2005Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C.Crit Rev Biochem Mol Biol40129154
- 9. Postic C, Dentin R, Girard J (2004) Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab 30: 398–408.C. PosticR. DentinJ. Girard2004Role of the liver in the control of carbohydrate and lipid homeostasis.Diabetes Metab30398408
- 10. Cummins EP, Taylor CT (2005) Hypoxia-responsive transcription factors. Pflugers Arch 450: 363–371.EP CumminsCT Taylor2005Hypoxia-responsive transcription factors.Pflugers Arch450363371
- 11. Bi Y, Cai M, Liang H, Sun W, Li X, et al. (2009) Increased carnitine palmitoyl transferase 1 expression and decreased sterol regulatory element-binding protein 1c expression are associated with reduced intramuscular triglyceride accumulation after insulin therapy in high-fat-diet and streptozotocin-induced diabetic rats. Metabolism 58: 779–786.Y. BiM. CaiH. LiangW. SunX. Li2009Increased carnitine palmitoyl transferase 1 expression and decreased sterol regulatory element-binding protein 1c expression are associated with reduced intramuscular triglyceride accumulation after insulin therapy in high-fat-diet and streptozotocin-induced diabetic rats.Metabolism58779786
- 12. Uyeda K, Repa JJ (2006) Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 4: 107–110.K. UyedaJJ Repa2006Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis.Cell Metab4107110
- 13. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F (2004) SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86: 839–848.D. EberleB. HegartyP. BossardP. FerreF. Foufelle2004SREBP transcription factors: master regulators of lipid homeostasis.Biochimie86839848
- 14. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, et al. (2002) Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277: 19353–19357.N. YahagiH. ShimanoAH HastyT. MatsuzakaT. Ide2002Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice.J Biol Chem2771935319357
- 15. Li H, Dong B, Park SW, Lee HS, Chen W, et al. (2009) Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 284: 28885–28895.H. LiB. DongSW ParkHS LeeW. Chen2009Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.J Biol Chem2842888528895
- 16. Cheng Z, Pang T, Gu M, Gao AH, Xie CM, et al. (2006) Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta 1760: 1682–1689.Z. ChengT. PangM. GuAH GaoCM Xie2006Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK.Biochim Biophys Acta176016821689
- 17. Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, et al. (2006) Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47: 1281–1288.JM BrusqN. AncellinP. GrondinR. GuillardS. Martin2006Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine.J Lipid Res4712811288
- 18. Zhou L, Yang Y, Wang X, Liu S, Shang W, et al. (2007) Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 56: 405–412.L. ZhouY. YangX. WangS. LiuW. Shang2007Berberine stimulates glucose transport through a mechanism distinct from insulin.Metabolism56405412
- 19. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, et al. (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51: 1584–92.NA GuptaJ. MellsRM DunhamA. GrakouiJ. Handy2010Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.Hepatology51158492
- 20. Kimball SR, Siegfried BA, Jefferson LS (2004) Glucagon represses signaling through the mammalian target of rapamycin in rat liver by activating AMP-activated protein kinase. J Biol Chem 279: 54103–9.SR KimballBA SiegfriedLS Jefferson2004Glucagon represses signaling through the mammalian target of rapamycin in rat liver by activating AMP-activated protein kinase.J Biol Chem279541039
- 21. Ko BS, Choi SB, Park SK, Jang JS, Kim YE, et al. (2005) Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull 28: 1431–1437.BS KoSB ChoiSK ParkJS JangYE Kim2005Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma.Biol Pharm Bull2814311437
- 22. Wang H, Liu D, Cao P, Lecker S, Hu Z (2010) Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine. Diabetes 59: 1879–1889.H. WangD. LiuP. CaoS. LeckerZ. Hu2010Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine.Diabetes5918791889
- 23. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, et al. (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14: 395–403.TN StittD. DrujanBA ClarkeF. PanaroY. Timofeyva2004The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.Mol Cell14395403
- 24. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, et al. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399–412.M. SandriC. SandriA. GilbertC. SkurkE. Calabria2004Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.Cell117399412
- 25. Mikes V, Dadak V (1983) Berberine derivatives as cationic fluorescent probes for the investigation of the energized state of mitochondria. Biochim Biophys Acta 723: 231–239.V. MikesV. Dadak1983Berberine derivatives as cationic fluorescent probes for the investigation of the energized state of mitochondria.Biochim Biophys Acta723231239
- 26. Mikes V, Yaguzhinskij LS (1985) Interaction of fluorescent berberine alkyl derivatives with respiratory chain of rat liver mitochondria. J Bioenerg Biomembr 17: 23–32.V. MikesLS Yaguzhinskij1985Interaction of fluorescent berberine alkyl derivatives with respiratory chain of rat liver mitochondria.J Bioenerg Biomembr172332
- 27. Barreto MC, Pinto RE, Arrabaca JD, Pavao ML (2003) Inhibition of mouse liver respiration by Chelidonium majus isoquinoline alkaloids. Toxicol Lett 146: 37–47.MC BarretoRE PintoJD ArrabacaML Pavao2003Inhibition of mouse liver respiration by Chelidonium majus isoquinoline alkaloids.Toxicol Lett1463747
- 28. Kong W, Wei J, Abidi P, Lin M, Inaba S, et al. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344–1351.W. KongJ. WeiP. AbidiM. LinS. Inaba2004Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.Nat Med1013441351
- 29. Zhang Y, Li X, Zou D, Liu W, Yang J, et al. (2008) Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93: 2559–2565.Y. ZhangX. LiD. ZouW. LiuJ. Yang2008Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.J Clin Endocrinol Metab9325592565
- 30. Wang L, Ye X, Li X, Chen Z, Chen X, et al. (2010) Metabolism, transformation and distribution of Coptis chinensis total alkaloids in rat. Zhongguo Zhong Yao Za Zhi 35: 2017–20.L. WangX. YeX. LiZ. ChenX. Chen2010Metabolism, transformation and distribution of Coptis chinensis total alkaloids in rat.Zhongguo Zhong Yao Za Zhi35201720
- 31. Wang X, Wang R, Xing D, Su H, Ma C, et al. (2005) Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract. Life Sci 77: 3058–67.X. WangR. WangD. XingH. SuC. Ma2005Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract.Life Sci77305867
- 32. Liu YT, Hao HP, Xie HG, Lai L, Wang Q, et al. (2010) Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos 38: 1779–84.YT LiuHP HaoHG XieL. LaiQ. Wang2010Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats.Drug Metab Dispos38177984
- 33. Yu Y, Liu L, Wang X, Liu X, Liu X, et al. (2010) Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol 79: 1000–6.Y. YuL. LiuX. WangX. LiuX. Liu2010Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies.Biochem Pharmacol7910006
- 34. Lu SS, Yu YL, Zhu HJ, Liu XD, Liu L, et al. (2009) Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J Endocrinol 200: 159–65.SS LuYL YuHJ ZhuXD LiuL. Liu2009Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats.J Endocrinol20015965